NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · PODD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Insulet Corp.’s quoted price sits in the lower half of its reported 52-week range, 57.03% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Insulet Corp.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $1.59. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Insulet Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 8, 2025 |
| $1.02+29.11% vs estimate |
| $569.00M+4.73% vs estimate |
| Q4 2024 | Feb 20, 2025 | $1.15+15.0% vs estimate | $597.50M+2.57% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | $0.90+18.42% vs estimate | $543.90M+4.69% vs estimate |
|---|
THE ANALYST VIEW
50 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 17 contributors · Median target $179.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
$79.93+$1.31 (+1.67%)
DexCom, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.67% below the high.
$19.79+$0.11 (+0.56%)
Tandem Diabetes Care, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.25% below the high.
$17.58-$0.27 (-1.51%)
Beta Bionics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.25% below the high.
$9.75+$0.41 (+4.39%)
Senseonics Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.36% below the high.
